Mucosal lesions of the stomach or duodenum are seen frequently in patients taking NSAIDs. The incidence of peptic ulcer has been reported to lie between 17% and 31%1-and elderly patients may be especially susceptible to NSAID associated peptic ulcer perforation.4 A variety of problems, such as lack of control groups, few prospective studies, multidrug therapy, etc, make it very difficult to reach firm conclusions as to the ulcerogenicity of NSAIDs' except for unbuffered aspirin, which is considered ulcerogenic.57 In a recent paper, however, it was reported that bleeding complications from peptic ulcers in patients over 60 years was correlated with use of non-aspirin NSAIDs.' The possible influence of NSAIDs on the ulcer healing process has been evaluated in only a few, mainly retrospective studies including a limited number of patients.`' This study compares the effects of ranitidine or sucralfate on the healing of peptic ulcer in patients with rheumatic disease, half of whom were randomised to continue on NSAID, while the remainder were given alternative analgesic therapy. After ulcer treatment patients were followed up for 12 months.
Methods

PATIENTS
Sixty seven consecutive patients from the four participating departments were included, 38 with Figure.
recorded daily on a 10 cm long visual analogue scale (0=no discomfort; 10=very severe discomfort). Three patients with severe arthritic pain at night received morphine analogues for a limited period of time; two of them had occasional treatment with opiates before inclusion in the trial. Ulcer healing was recorded endoscopically every three weeks. The endoscopist had no knowledge of the drugs being taken. If an ulcer had not healed after nine weeks, the treatment was changed to the other antiulcer drug, but NSAID treatment or nontreatment was not changed.
After ulcer healing the patients were followed for 12 months, attending the rheumatological outpatients clinics at regular intervals. Patients in whom NSAIDs had been stopped were free to start such treatment. Patients developing dyspepsia during the follow up period were re-endoscoped to confirm the diagnosis.
DURATION OF STUDY AND STATISTICS
The study was planned to include 80 patients. For practical reasons, however, entry was closed after two years when 67 patients had been entered. Chisquare test with Yates's correction for continuity was used. A 5% significance level was chosen.
ETHICAL CONSIDERATIONS
We did not think it justified to include a placebotreated group because of the many effective and well tolerated antiulcer drugs available today. 12 The investigation was approved by the regional ethical committees, and all patients gave their informed consent.
Results
Of the 67 patients recruited to the study, 51 had a duodenal or prepyloric ulcer, 14 Table 3 shows that the proportion of healed ulcers and the mean healing time were similar in patients given either ranitidine or sucralfate. In 10 patients with persistent ulcer after nine weeks of treatment, continued therapy with the alternative anti-ulcer drug resulted in healing in seven patients after a further three to nine weeks of treatment. Table 4 shows the results of ulcer treatment in patients who continued on a NSAID in comparison with patients in whom the NSAID was discontinued. There were no differences in the healing rates and the mean healing time between the various subgroups. The 14% difference between NSAID takers and nontakers in overall healing rate is not statistically significant (X2=2-23; p>0-10).
Median values for the visual analogue scale of ulcer symptoms were 2-8 (range 0-10) at the time of entry; 1.4 (range 0-8) after one week of treatment, and 0-7 (range 0-6) after three weeks. Very few patients had dyspeptic complaints after the initial three weeks of ulcer therapy. Thirty patients, with an equal representation in the treatment groups, reported antacid use equivalent to a neutralising capacity of 15-50 mmol/day (24 patients) and from 50-75 mmol/day in the remainder. Antacid consumption was unusual after the first three weeks of ulcer therapy.
During the 12 months follow up 14 of 32 patients randomised to withdrawal of NSAIDs, resumed this treatment whereas 15 of 30 patients randomised to continued NSAIDs gave up the same. Symptomatic ulcer recurrences were documented in 14 patients (eight smokers), nine of whom took NSAIDs at the time of relapse. The recurrences were evenly distributed in the four randomisation groups (Figure) . Ulcer rehealing was shown endoscopically in 10 of these patients after three to six weeks of treatment with either of the two ulcer regimens. Two patients died during the follow up, but death could not be associated with complications of the peptic ulcer disease.
There were very few and non-specific complaints of adverse reactions possibly related to ranitidine or sucralfate. Routine laboratory screening tests did not show any abnormalities, except for a transient rise in S-creatinine in one patient.
Discussion
Withdrawal of salicylates and other NSAIDs is generally recommended to a patient with a peptic ulcer. This trial has shown that ulcer treatment can be accomplished in spite of continuous administration of NSAIDs. The patients received a broad spectrum of NSAIDs and five were given aspirin, which is likely to cause more mucosal damage than the other NSAIDs.'3 The conclusions of our study would be unchanged, even if the five aspirin takers had been excluded from the analyses.
Sucralfate, a non-absorbable 'cytoprotective drug' with proven efficacy in the treatment of peptic ulcer'4 was compared with ranitidine, a potent H2-receptor blocker.'5 Both drugs can be expected to heal 85-90% of peptic ulcers after eight weeks of treatment. The randomisation procedure guaranteed an even distribution of patients in the four treatment groups as well as a balanced representation of the two major rheumatic disorders, rheumatoid arthritis and osteoarthritis, within these groups. It is therefore permissible, in later calculations, to combine the diagnostic and/or treatment groups as appropriate. Virtually, the same healing rate and mean healing time were found for ranitidine and sucralfate. The Table 3 Results ofpeptic ulcer treatment with ranitidine or sucralfatefor up to nine weeks in 62 patients with rheumatic disease. proportion of healed ulcers rose from 31/62 (50%) at three weeks to 52/62 (84%) at nine weeks. This corresponds with results from studies involving nonrheumatic patients. Non-steroidal anti-inflammatory drug takers with gastric ulcers tended to heal more slowly, or not at all within nine weeks, but seven of 10 persistent ulcers did heal after a total of 12-18 weeks of treatment.
Asymptomatic ulcer recurrences were not registered. This is in accordance with the entry criteria of dyspepsia. Excluding the two patients who died during follow-up, the recurrence rate was 0-23 (95% confidence limits: 0-13-0-36). This is probably a minimum estimate as can be judged from studies in non-rheumatic patients'6 which, however, often include asymptomatic ulcers found at endoscopy at fixed intervals during the follow-up period.
From the results of this study, we suggest that NSAIDs should not be stopped if a peptic ulcer is diagnosed in a patient with active rheumatic disease. According to our experience, ulcer therapy can be carried through effectively in parallel with antiinflammatory treatment. Our data show that ranitidine and sucralfate have equal ulcer-healing efficacy and that there is no difference regarding the outcome of ulcer treatment in patients with either rheumatoid arthritis or osteoarthritis.
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